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Abstract
Background: Published formulas for case-control designs provide sample sizes required to
determine that a given disease-exposure odds ratio is significantly different from one, adjusting for
a potential confounder and possible interaction.
Results: The formulas are extended from one control per case to F controls per case and adjusted
for a potential multi-category confounder in unmatched or matched designs. Interactive FORTRAN
programs are described which compute the formulas. The effect of potential disease-exposure-
confounder interaction may be explored.
Conclusions: Software is now available for computing adjusted sample sizes for case-control
designs.
Background
Breslow and Day [1] and Smith and Day [2] provide as-
ymptotic formulas for the computation of case-control
sample sizes required for odds ratios, unadjusted or ad-
justed for a confounder [1] and for stratified matched de-
signs [2]. The notation we use is their notation. Their
formulas are extended here to include more than one con-
trol per case. The formulas for stratified matched were de-
duced from applying the approach of Breslow and Day [1]
(pages 305–6) to Table 7 of [2]. Modification of the for-
mulas for specified interactions [1,3] is also shown. These
formulas are based on the logarithm of the odds ratio, for
which the normal approximation is more accurate than
for the exposure difference, so these formulas are more ac-
curate than the exposure difference formula that is given
in the majority of general methods references [4,5].
Two conversational FORTRAN programs, DAYSMITH and
DESIGN, compute the formulas. They were submitted to
STATLIB for non-commercial distribution a few years ago,
and are obtained with an e-mail message such as "send de-
sign.exe from general" to  [statlib@lib.stat.cmu.edu] . The
programs produce a table of numbers of cases and con-
trols required for a variety of specifications of Type I and
Type II error, adjusted for the confounder, unadjusted,
and adjusted for stratified matching, with the strata being
the levels of the confounder. The two programs have dif-
ferent input requirements. Program DAYSMITH asks for
exactly the items required for the Smith and Day formu-
las. Program DESIGN accepts alternative input that is con-
verted in the program to the items required for the same
formulas. The formulas used are shown in Appendix 1.
Results
The input to program DAYSMITH
The sample sizes computed are for the detection of a given
disease-exposure odds ratio, that is, the sample sizes at
which a certain statistical test will reject the null hypothe-
sis that the odds ratio is one. The input items are as fol-
lows:
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RE = the odds ratio to be detected (typically a minimum
value),
S = 1 or 2 for one-sided or two-sided type I error,
F = the number of controls per case,
P = the control population exposure probability, and
I = an indicator to request interaction adjustment.
Roughly speaking, interaction in statistics corresponds to
effect modification in epidemiology. By not selecting an
interaction adjustment, we effectively assume that the dis-
ease-exposure odds ratio does not differ across confound-
er levels. Interaction is discussed further below.
The number of confounder levels, denoted K is asked for
next. If K = 1, unadjusted sample sizes only are computed,
and no other input is required. Program DESIGN is iden-
tical to this point. For most applications, no confounder
adjustment is required and so the program returns unad-
justed sample sizes and is finished after a 1 is entered for
K. The unadjusted formula [1] is more accurate than the
usual unadjusted formulas [4,5], and may therefore pro-
duce different sample sizes than those.
If K > 1, one of the levels of the confounder is taken to be
a reference level, and is referred to as level one. The order
of the levels is otherwise immaterial. The input required
next is three numbers for each of the K–1 remaining lev-
els, p1i, p2i, and RCi, i = 2,..., K, which are
p1i = Pr(Ci|E) = among the exposed population, the pro-
portion at level i of the confounder,
 = among the unexposed population,
the proportion at level i of the confounder, and
RCi = the disease-confounder odds ratio (with confounder
level i versus level 1).
For the reference level, we set Rc1 = 1 for the formulas that
follow. We compute 
 and  .
Input for program DESIGN
Whereas DAYSMITH asks for the same input as requested
in the original references [1–3], we found that alternative
input made more sense for our initial applications [6,7],
so a second program was written. The input for DESIGN
is the same as for DAYSMITH up to the point after which
the number of levels of the confounder, K, is asked for.
Again, one of the levels of the confounder is taken to be a
reference level, and is referred to as level one. The input
that is required next is one number for the reference level,
ri, and then three (four when interaction is included)
numbers for each of the K–1 remaining levels, ri, pi, and
RCi, i = 2,...,K, which are
ri = Pr(E|Ci) = the probability of exposure at level i of the
confounder,
pi = Pr(Ci) = the probability of being in level i of the con-
founder, and
RCi = the odds ratio of disease and confounder level i (ver-
sus level 1).
For the reference level, we again set RCi = 1.
From Bayes Theorem, we compute
p1i=ripi/P and p2i=(1 – ri)pi/(1 – P).
We have one more input item than is actually required,
and that is used for a check, where we can use the fact that
What we actually do is check the sum
The sum ∆  is supposed to be equal to one. If it is not one,
then we re-define and report 
and 
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ri with 
i = 1,..., K, which is how the program used to report the
change.
An example, adjusting for a confounder
The following example is one of several computations
performed for a published research protocol for a study of
the association of oral contraceptive (OC) use with cardi-
ovascular risks, controlling for age group [6]. A related
protocol [7] has smoking as a confounder.
The numbers entered for P, ri, pi, and RCi, i = 2,...,K, are all
taken from the Saskatchewan government medical data-
base, which includes the entire population from which a
case-control sample is to be taken. In many applications,
such numbers are not available from a reliable source. In
that case, one may try sets of alternative minimum and
maximum numbers for a range of results. The maximum
sample sizes obtained from such sensitivity analyses
would be the conservative recommendation.
Both programs first request RE to I. For RE, the outcome of
interest is hospitalisation due to certain cardiovascular
risks. The exposure is a specific OC with 10% of the mar-
ket share [7]. Since overall OC prevalence is 30%, then P
= .03 for that specific OC. Using > to denote the cursor for
computer entry, we type:
>2 2 3 .03 0
for RE, S, F, P and I, respectively, then press enter. We then
receive the message:
Type the number of confounder levels, and <enter>. Type 1 if
no confounder.
We enter 5 levels and press enter.
>5
Now type in the population exposure probability for the refer-
ence level of the confounding variable.
This will be put at level 1, so it is Pr(E|C1)
The confounder levels are five age groups, and level 1 cor-
responds to the youngest age group 15–21, for which we
enter the prevalence for a specific OC with 10% of the
market share. We type .055 and press enter.
> .055
The reply is:
Now type in, for each of the other 4 level(s) of the confounding
variable, Pr(E|Ci), Pr(Ci), and Rc(i), separated by at least one
blank or <enter>, where Pr(E|Ci) = in the population at level i
of the confounder, the proportion exposed, Pr(Ci) = the proba-
bility of being at level i, and Rc(i) = odds ratio of disease and
confounder level i (versus level 1).
The following numbers are entered for age groups 22–26,
27–31, 22–39 and 40+:
> .038 .24 2
> .021 .2 8
> .008 .18 8
> .004 .15 28.5
Note that Rc(5) = RC5 = 28.5, a very high value. That is to
be expected if all older women are included. (For the final
protocol [6], a cut-off was made at age 45.) When enter is
pressed, we receive some confirmation of the input, and a
message that the result is written to file design.out. That is,
as currently written, the sample sizes and other output are
not automatically shown on the screen, but are saved in
"design.out" to be viewed directly there. Appendix 2 (Sec-
ond attached file, app2.txt, a text file) shows the output
from the preceding session, which includes a correction of
the input values.
Looking at Appendix 2, we see unadjusted sample sizes,
those adjusted for age in an unmatched study, and a third
set of sample sizes for a matched case-control study. For
our example [6], both unmatched and matched designs
are considered. With the low value of P and the high value
RC5, we see that a large difference in sample sizes required
for either design may result. In most applications, howev-
er, the differences are not so dramatic.
Adjusting for a matching confounder
Epidemiological literature usually gives formulas for
matching which are based on the strong assumption that
all sources of extraneous variation among a case and its
controls are accounted for [1,8,9]. A third program
DESIGNM was written to compute such a formula (from
[1], p.294), but DESIGNM does not adjust for a con-
founding variable, and that strong assumption of implicit
matching is rarely justified in case-control studies, so this
program was not made freely available. Software which
compute sample sizes for conditional logistic regression,
s u c h  a s  E G R E T  S I Z [ 1 0 ] ,  a r e  a l t e r n a t i v e s  t o  D E S I G N M ,
which is based on Miettinen's test of the Mantel-Haenszel
odds ratio for matched case-control designs. The adjust-
ment in DAYSMITH and DESIGN is for stratified match-
ing [2,11,12], where matching is by confounders. This
! rr ii =∆BMC Medical Research Methodology 2001, 1 http://www.biomedcentral.com/1471-2288/1/11
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presumes that the eventual analysis will be unconditional
[2] and will account for the stratification. Consequently, it
is not required that F controls be linked with each case,
only that the total number of controls be F times the total
number of cases.
Interaction
The literature [1,3,13,15] discusses stratified analysis in-
teraction adjustment only for confounders with K = 2. It is
easy, however, to modify the formulas for multi-level in-
teraction. Every occurrence of RE in the formulas (Appen-
dix 1) is replaced by RERIj, where RIj is the interaction
factor corresponding to the jth level, j = 2,..., K. (For ', put
RIj inside the first sum.) We set RI1 = 1.
For two confounder levels, RI2, which is RI in Smith and
Day's notation [3], is the multiplicative factor by which
the odds ratio for those exposed and in level 2 of the con-
founder is different from the odds ratio when there is con-
founder-exposure-disease interaction. For RIj, contrast is
between level j and the reference level (level one).
This adjustment was made available for sensitivity analy-
sis; specifically, to explore how much the sample size re-
sult could change if the confounder were in fact an effect
modifier. Nevertheless, the adjusted formulas have been
used to determine sample size in the presence of gene-en-
vironment interaction [13].
Discussion
The competitors to these programs are regression-based
sample size programs, such as those in EGRET SIZ [10],
which compute sample sizes required for unconditional
logistic regression. The package nQuery [14] has an un-
conditional logistic regression option, but is not set up for
case-control designs. These may be useful for continuous
exposures, and make sense when the final analysis is in-
tended to be such a regression, rather than a stratified
analysis, such as a Mantel-Haenszel test, which our pro-
grams correspond to. We are unaware of any generally
available competitor for stratified analysis.
In a series of papers on sample-size estimation to detect
gene-environment interaction, which is a controversial
role for sample-size formulas, comparisons have been
made between regression based approaches and the strat-
ified analysis approach [13,15]. One solution is even to
consider a case-only design [16]. EGRET SIZ provides no
guidance for interaction adjustment, but it probably could
be used for that purpose.
When there is more than one confounder, we define one
super-confounder, where each category corresponds to a
sub-category. For example, if age, with 5 categories, and
smoking, with 2 categories, are both confounders, then
we define one super-confounder with 10 = 5 ×  2 catego-
ries. The estimates of ri, pi, and RCi, i = 2, ...,10, then all
have to take age and smoking into account jointly. As the
number of confounders and the size of K increases, regres-
sion-based sample size programs become more advanta-
geous, since information is not required for every sub-
category.
The current programs yield results for 80% and 90% pow-
er, but versions are available for alternative powers, from
60% to 95%. A new version may print to the screen, if us-
ers want that option, and ask whether sample sizes for a
specific power and Type I error are required.
The programs described are for two levels of disease (case
vs. control) and of exposure. For several levels of exposure
or disease, measures are available which correspond to
odds ratios, risk ratios and risk differences [17], and it is
not difficult to compute sample size formulas for these. If
there is some demand, software to do those calculations
may be created.
The Breslow-Day-Smith formulas which we extend utilize
the classical method, based on testing. A more modern ap-
proach is that based on a confidence interval for the odds
ratio [18], which may eventually become a program op-
tion. A Bayesian approach seems most suited for the sam-
ple size problem, although some issues need to be
resolved [19]. Although not yet written, a Bayesian solu-
tion will soon be formulated for case-control designs.
Competing interests
none declared
Acknowledgement
The author is supported by an Équipe grant from the FRSQ (Fonds de la 
recherche en santé du Québec). I appreciate the input of Eric Johnson, Sho-
lom Wacholder and Jesse Berlin.
Additional material
Appendix files
Appendix 1 - Shows the formulas utilized by DESIGN and DAYSMITH. 
Appendix 2 - Shows output from the DESIGN session described in the 
main text.
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